LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
12-week randomized phase 1b trial in adults with type 2 diabetes
How the study was set up
A blinded, randomized phase 1b study enrolled 72 adults with type 2 diabetes for 12 weeks, with placebo and a small dulaglutide comparison group.
What the researchers measured
Safety and tolerability were primary; drug concentrations, glucose, HbA1c, and body weight were additional measures.
How to read this evidence
The paper includes research in people. Its comparison groups, participant selection, follow-up, and measured outcomes determine how far the findings can be applied. The label alone does not establish efficacy or safety.
Results in context
Twenty-nine participants discontinued early, and gastrointestinal problems were common. The short, small study was designed for early development rather than definitive efficacy or long-term safety.
What this does not establish
A small early-phase trial with treatment discontinuations provides limited information about uncommon harms and long-term outcomes.
Publication & source
Why this paper is included
The compound is a named subject of the publication title.
Publication indexing
Randomized Controlled Trial · Multicenter Study · Clinical Trial, Phase I · Journal Article